Selank: Anxiolytic Peptide Research Overview

September 28, 2026 · By My Store 3 Admin

Selank is a synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), with a Pro-Gly-Pro extension at the C-terminus. Like Semax, it was developed in Russia — at the Institute of Molecular Genetics of the Russian Academy of Sciences — and has been investigated primarily for its proposed anxiolytic, anti-stress, and nootropic properties. It represents a distinct mechanistic profile from Semax despite sharing the same research origin and general compound class.

This article provides a research-focused overview of Selank’s molecular profile, proposed mechanisms, and published research. All Bloom Vitality products are supplied strictly for in vitro laboratory and research use only.

Molecular Profile

Selank has the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro — the tetrapeptide tuftsin sequence with a stabilising Pro-Gly-Pro extension that increases resistance to enzymatic degradation and extends the compound’s biological half-life. The modification converts a rapidly degraded endogenous peptide into a more tractable research compound. Selank is water-soluble and stable in lyophilised form.

Tuftsin is a naturally occurring tetrapeptide produced by the spleen through enzymatic cleavage of immunoglobulin G. It is known primarily for its immunostimulatory properties, but the tuftsin sequence also serves as the structural basis for Selank’s proposed CNS activity.

Proposed Mechanisms

Enkephalin system modulation — Selank is proposed to inhibit enkephalin-degrading enzymes (enkephalinases), increasing the availability of endogenous opioid peptides (met-enkephalin and leu-enkephalin). This effect on the enkephalin system is considered the primary proposed mechanism for Selank’s anxiolytic properties.
GABAergic modulation — some research proposes that Selank modulates GABA receptor function, contributing to anxiolytic-like effects in animal models, though this mechanism is less well-characterised than the enkephalin pathway.
Serotonergic effects — studies have reported Selank-associated changes in serotonin system parameters, including serotonin transporter expression and 5-HT availability.
BDNF modulation — similar to Semax, some research has reported Selank-associated changes in BDNF expression, though this is less central to Selank’s proposed mechanism than for Semax.
Immune system interaction — reflecting the tuftsin structural basis, some research has investigated Selank’s effects on cytokine profiles and immune cell activity.

Areas of Preclinical and Clinical Research

Anxiolytic effects in rodent models (elevated plus maze, open field, social interaction tests)
Anti-stress effects and adaptation to chronic stress
Memory consolidation and learning performance
Cytokine and immune profile modulation
Early-phase clinical investigation in Russia for generalised anxiety and stress-related conditions (limited, non-Western peer-reviewed data)

Evidence Landscape

The Selank literature shares several characteristics with the Semax evidence base:

Geographic concentration — published research originates predominantly from Russian institutions; independent Western replication is limited
Preclinical focus — the majority of evidence comes from rodent behavioural models; anxiolytic effects are consistently reported across multiple assays
Mechanistic characterisation — the enkephalin system hypothesis has reasonable mechanistic support from in vitro enzyme inhibition studies and is the most coherently evidenced proposed mechanism
Clinical data — clinical use in Russia for anxiety-related conditions has been reported but does not meet the methodological standard of peer-reviewed randomised controlled trials in Western regulatory contexts

Selank vs Semax

The two principal nootropic peptide compounds from Russian research programmes are often considered alongside each other:

Selank — proposed anxiolytic, calming, anti-stress effects; primary mechanism via enkephalin system; generally considered inhibitory/modulating in character
Semax — proposed cognitive-enhancing, focus-promoting effects; primary mechanism via BDNF/NGF upregulation and melanocortin receptor interaction; generally considered activating in character

For a full overview of Semax, see: Semax: Nootropic Peptide Research Overview.

UK Research Context

Selank is not classified as a controlled substance in the UK and is available as a research material for in vitro laboratory use. Researchers should refer to the UK regulatory framework for research peptides for the relevant legislative context, and should verify the current regulatory status for their specific research application.

Research Material

Bloom Vitality supplies Selank 10mg as a lyophilised research compound, independently third-party tested for purity and potency. Our Selank research material is part of the broader research peptides UK catalogue. Batch-specific Certificates of Analysis are available via our Certificates & Documentation page and Testing & Quality page.